BUTYROSPERMUM PARKII BUTTER
화장품에서 쉐어버터 (BUTYROSPERMUM PARKII BUTTER)의 글로벌 배합 한도와 핵심 효능·처방 기준은 무엇인가요?
쉐어버터(표준 INCI: BUTYROSPERMUM PARKII BUTTER, CAS 번호: 194043-92-0)은 화장품 처방에서 주로 피부컨디셔닝제, 점도조절제 목적으로 배합되는 핵심 원료입니다. 한국 식약처(미규제) 및 유럽 CosIng(미규제) 등 6대 권역 법정 기준 하에 관리되며, 통상 1–23%(적정 pH 4–8) 범위에서 안정적으로 처방됩니다.
7대 갈래 국가별·용도별 공식 전성분 라벨 표기명 매트릭스
각국 1차 법원 고시 정본 · 기계번역·임의 음차 0건| 국가·규제 트랙 | 공식 고시 전성분 표기명 | 원클릭 복사 |
|---|---|---|
| ① 한국 (MFDS 화장품 한글 표준명) | 쉐어버터 | |
| ② 한국 구명칭 (개정 전 이력 · 301 리다이렉트) | — | — |
| ③ 유럽 (EU CosIng EC 1223/2009) | BUTYROSPERMUM PARKII BUTTER | |
| ④ 미국 일반화장품 (US PCPC / MoCRA INCI) | BUTYROSPERMUM PARKII (SHEA) BUTTER | |
| ⑤ 미국 OTC (FDA Active Ingredient Monograph) | — (비-OTC 일반 화장품 원료) | — |
| ⑥ 중국 (NMPA IECIC 표준 중문명) | 미등재 — 중국 《기사용화장품원료목록(IECIC)》 미수록 (임의 번역 금지) | — |
| ⑦ 일본 일반화장품 / 의약부외품 (JCIA / MHLW) | BUTYROSPERMUM PARKII BUTTER (표준 INCI 기준 · 임의 가타카나 변환 배제) |
Layer 1 — 글로벌 6대 권역 법정 배합 한도 및 규제 상태
| 권역 | 규제 상태 | 배합 한도 | 제한 조건 및 1차 법원 출처 |
|---|---|---|---|
| 한국 (MFDS) | 미규제 | GMP | 공식 화장품 원료 목록 등재 (GMP 기준 사용) |
| 유럽 (CosIng) | 미규제 | GMP | 공식 화장품 원료 목록 등재 (GMP 기준 사용) |
| 미국 (FDA/CIR) | 미규제 | GMP | 공식 화장품 원료 목록 등재 (GMP 기준 사용) |
| 중국 (NMPA) | 미규제 | GMP | 공식 화장품 원료 목록 등재 (GMP 기준 사용) |
| 일본 (MHLW) | 미규제 | GMP | 공식 화장품 원료 목록 등재 (GMP 기준 사용) |
| 아세안 (ACD) | 미규제 | GMP | 공식 화장품 원료 목록 등재 (GMP 기준 사용) |
Layer 3 제형군별 통상 배합 농도(%) 레인지 & Layer 1 법정 한도 대조
Layer 3 — 제형군별 통상 배합 농도(n≥5 사분위수) & 물리화학·상용성 가이드
| 제형군 분류 | Min – Q1 – Median – Q3 – Max (%) | 처방 역할 및 기전 | Source ID |
|---|---|---|---|
| 제형군 E — 무수 오일 · 멀티밤 · 립케어 | 1% · 2% · 5% · 10% · 23% | 무수 밤·스틱·오일 처방 유상 골격 및 보습막 형성 | Global Starter Formulation Library Statistical Distribution (n=5, SEPPIC 3 · EVONIK 2) |
| 제형군 C — 세정 워시오프 · 폼 · 샴푸 · 바디워시 | 3% · 3% · 5% · 11.5% · 11.5% | 린스오프 세정·클렌징 처방 계면 안정화 및 사용감 개선 | Global Starter Formulation Library Statistical Distribution (n=5, EVONIK 5) |
| 제형군 B — 유화 로션 · 에멀전 · 크림 (O/W · W/O) | 1% · 1% · 1% · 1.75% · 9.8% | 유화 로션·크림 제형 구조 형성 및 피부 컨디셔닝 | Global Starter Formulation Library Statistical Distribution (n=6, EVONIK 2 · GRANT 2 · SEPPIC 2) |
각질층 장벽 투과 깊이 & 바이오 스피큘 경피전달(DDS) 시뮬레이션
단독 도포 시 각질층 세포간 지질(Brick & Mortar) 경로를 통해 확산됩니다. 500 Dalton 이상 친수성 분자는 각질층 표면에 주로 머물러 보습·보호막 역할을 수행합니다.
pH 안정성 스펙트럼(0~14) · 가열 한계 게이지 · HLB 콜로이드 상거동
권장 구간 밖(pH < 4 또는 pH > 8)에서는 가수분해·점도 저하·이온 탈리 위험이 증가합니다.
최대 50°C 가열 공정에서 열적 안정성이 유지됩니다.
세포·분자 타깃 작용 기전 플로우 다이어그램
권장 시너지(🟢 실선) & 배합 금기·주의(🔴 점선) 인터랙티브 관계도
🟢 초록색 시너지 원료 노드를 클릭하면 해당 원료 모노그래프로 즉시 이동하며, 🔴 붉은색 점선 노드를 클릭하면 화학적 상충(석출·변색·실활) 메커니즘을 표시합니다.
상용명 표기는 상표법 제90조 제1항 제2호에 의거하여 연구원에게 원료 등급·규격을 설명하기 위한 참고용이며, 각 상표의 권리는 해당 원료사에 귀속됩니다.
학술·독성·제형 종합 요약 (Tier 1~3 탄력 요약)
Tier 1 Synthesis이 원료에 매칭된 PubMed 동료심사 논문 초록과 공인 독성 보고서만으로 작성된 학술 요약입니다.
근거 동료심사 학술 논문 (미국 NIH PubMed) (6)
A novel treatment of diaper dermatitis in children and adults [PMID: 33934478 · 2021]
Diaper dermatitis (DD) is an acute inflammatory reaction, regardless of the cause, of the diaper-covered area. Topical skin barrier repair cosmetic products are the mainstay treatment to cure and/or prevent DD. To assess the efficacy/tolerability of a zinc gluconate-taurine/zinc oxide and panthenol/ glycerin/ Butyrospermum parkii butter barrier cream using clinical evaluation. In this prospective, open-label trial, 20 patients (10 infants/10 adults), with mild/moderate DD enrolled at the Dermatology University Clinic of Catania (Italy) were instructed to apply the cream twice daily for 30 days. Degree of erythema was performed clinically by a 5-point severity scale (from 0 = no erythema to 4 = severe erythema), at baseline, at 15 and 30 days. An Investigator Global Assessment (IGA) using a 6-point scale (from -1 = worsening to 4 = complete response/clear) along with product tolerability was also performed at 15 and 30 days. Statistical analysis was performed using SAS version 9. At 15 days, a reduction of clinical erythema assessment (CEA) from baseline was observed (mean from 3.2 ± 0.8 to 2.5 ± 0.3; p < 0.06), that although nonsignificant, showed a significant progressive improvement at 30 days (mean from 3.2 ± 0.8 to 1.1 ± 0.9; p < 0.0001) without any age differences. Our preliminary results indicate that the tested barrier cream may represent a promising approach in DD rash. It may be used in mild-to-moderate forms in monotherapy without significant side effects or, where required, in association with pharmacological agents. Its long-term use is likely safe.
A novel treatment of intertrigo in athletes and overweight subjects [PMID: 33934472 · 2021]
Intertrigo is a recurrent inflammatory dermatosis involving large/small body folds. Skin barrier products represent the mainstay of treatment in uncomplicated mild/moderate intertrigo. To assess by clinical and instrumental evaluation the efficacy and tolerability of a new barrier spray containing zinc gluconate-taurine complex and zinc oxide combined with panthenol, glycerin, and Shea (Butyrospermum parkii) butter in mild-to-moderate intertrigo in athletes and overweight subjects. In this open-label prospective trial, 20 adult patients, with mild/moderate intertrigo enrolled at the Dermatology University Clinic of Catania (Italy), were instructed to apply the spray twice daily for 30 days. Degree of erythema was performed clinically and by polarized dermoscopy using a 5-point severity scale (from 0=no erythema to 4=severe erythema) at baseline, and at 15 and 30 days. The measurement of pruritus was carried out by a subject-completed visual analog scale (VAS) (from 0 mm=no pruritus to 100 mm=severe pruritus), at all time points. An Investigator Global Assessment (IGA) using a 6-point scale (from -1=worsening to 4=complete response/clear) was also conducted at 30 days, along with a self-administered tolerability questionnaire. Statistical analysis was performed using SAS version 9. At 15 days, a statically significant reduction from baseline in erythema severity (mean from 3.4 ± 0.3 to 2.5 ± 0.2) along with pruritus intensity (mean from 70 ± 15.4 mm to 40 ± 9.5 mm) was observed. At 30 days, all evaluated parameters showed a further progressive statistically significant reduction from baseline. No relevant side effects were recorded. Our results suggest that the tested spay containing antiseptic/anti-inflammatory and anti-irritation agents may represent a valid therapeutic option for mild/moderate intertrigo.
Butyrospermum parkii butter increased the photostability and in vivo SPF of a molded sunscreen system [PMID: 32385930 · 2020]
Ultraviolet (UV) radiation exposure is related to skin and lip tumors. Therefore, the development of photoprotective lipstick formulations is of utmost importance. Considering the biological properties of Shea butter (Butyrospermum parkii), we assessed its potential as an adjuvant in a molded lipstick sunscreen system by in vivo tests and photostability. Shea butter was used in a photoprotective lipstick formulation at two different concentrations (10.0% and 15.0% w/w) associated with ethylhexyl methoxycinnamate (EHM) and titanium dioxide. Skin compatibility was assessed in vivo. The in vivo SPF value was determined according to the current recognized method. Additionally, the photostability of EHM was determined by high-performance liquid chromatography. By the cutaneous compatibility, the product presented no interference with skin barrier and no adverse reactions, thus proving its safety. The in vivo SPF assay showed that the highest concentration of Shea butter increased the in vivo SPF value of the sample by 35%, demonstrating it to be a booster in photoprotective lipstick formulations. Also, Shea butter was proved to enhance the photostability of EHM, a commonly used UVB filter available in several countries. Shea butter increased the photostability and in vivo SPF of a molded lipstick sunscreen.
Influence of Shea (Butyrospermum parkii) butter, TiO(2) and ethylhexyl methoxycinnamate on physical parameters and in vitro photoprotective efficacy [PMID: 31856404 · 2020]
The development of photoprotective lipsticks containing natural bioactive compounds is a relevant current strategy to increase sun protection factor (SPF) value and lower the concentration of chemical UV filters, known for promoting sensitivity reactions. Twelve photoprotective lipsticks were developed by Design of Experiment (DOE) and characterized to verify the influence of Shea butter (Butyrospermum parkii), titanium dioxide (TiO 2 ), and ethylhexyl methoxycinnamate (EHM) on physical parameters and in vitro photoprotective efficacy. The influence of Shea butter, TiO 2, and EHM was evaluated by several parameters, such as melting point, colorimetry, thermal analysis by DSC, texture analysis, and sunscreen activity estimated in vitro. The construction of prediction models was possible for the following responses: maximum force by the cantilever test at 25 and 45°C; maximum distance by hardness test at 25°C; slope value at 25 and 45°C by the cantilever test; and UVA/UVB ratio and in vitro SPF. TiO 2 and EHM contributed to changes on the in vitro SPF value; however, unexpectedly, Shea butter had no influence on this efficacy parameter. The assay allowed us to observe the influence of the variables in the analysis and to develop a response prediction model for some of the parameters assessed.
Contact allergy to Butyrospermum parkii butter in a patient with cheilitis [PMID: 38123238 · 2024]
Fast non-aqueous reversed-phase liquid chromatography separation of triacylglycerol regioisomers with isocratic mobile phase. Application to different oils and fats [PMID: 28039812 · 2017]
The distribution of fatty acid species at the sn-1/3 position or the sn-2 position of triacylglycerols (TAGs) in natural fats and oils affects their physical and nutritional properties. In fats and oils, determining the presence of one or two regioisomers and the identification of structure, where they do have one, as well as their separation, became a problem of fundamental importance to solve. A variety of instrumental technics has been proposed, such as MS, chromatography-MS or pure chromatography. A number of studies deal with the optimization of the separation, but very often, they are expensive in time. In the present study, in order to decrease the analysis time while maintaining good chromatographic separation, we tested different monomeric and polymeric stationary phases and different chromatographic conditions (mobile phase composition and analysis temperature) using Non-Aqueous Reversed Phase Liquid Chromatography (NARP-LC). It was demonstrated that mixed polymeric stationary bonded silica with accessible terminal hydroxyl groups leads to very good separation for the pairs of TAGs regioisomers constituted by two saturated and one unsaturated fatty acid (with double bond number: from 1 to 6). A Nucleodur C18 ISIS percolated by isocratic mobile phase (acetonitrile/2-propanol) at 18°C leads to their separations in less than 15min. The difference of retention times between two regioisomers XYX and XXY are large enough to confirm, as application, the presence of POP, SOP, SOS and PLP and no PPO, SPO, SSO and PPL in Theobroma cacao butter. In the same way, this study respectively shows the presence of SOS, SOP and no SSO, PSO in Butyrospermum parkii butter, POP, SOP, SOS and no PPO, PSO and SSO in Carapa oil and finally POP and no PPO in Pistacia Lentiscus oil.
자주 묻는 질문 (AEO 스니펫 최적화 FAQ)
- Q1. 쉐어버터 (BUTYROSPERMUM PARKII BUTTER)의 국가별 공식 전성분 표기명은 어떻게 다른가요?
- 한국 식약처 표준명은 '쉐어버터', 미국 PCPC 및 유럽 CosIng INCI 표기는 'BUTYROSPERMUM PARKII (SHEA) BUTTER', 중국 NMPA IECIC 표준명은 '중국 IECIC 미등재(기계번역 금지)', 일본 화장품 표시명칭은 'BUTYROSPERMUM PARKII BUTTER'입니다.
- Q2. 쉐어버터의 글로벌 6대 권역 법정 배합 한도(Layer 1)는 무엇인가요?
- 한국(KR: none), 유럽(EU: none), 미국(US: none), 중국(CN: none), 일본(JP: none), 아세안(ASEAN: none) 고시 기준을 준수하여 처방해야 합니다.
- Q3. 제형 설계 시 쉐어버터의 통상 배합 농도(Layer 3)와 적정 pH는 얼마인가요?
- 대표 제형군(anhydrous_balm) 기준 통상 1~23%(권장 중앙값 5%) 범위로 투입하며, 적정 pH는 4~8입니다.
- Q4. 쉐어버터 배합 시 주의해야 할 상용성 금기(Incompatibilities)와 시너지 성분은 무엇인가요?
- 주요 권장 시너지 조합은 GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL이며, 배합 주의사항은 처방 내 극단적 pH 조건 및 고농도 전해질과의 상용성 사전 확인 권장입니다.